Daré Bioscience Announces Reverse Stock Split
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) --...
Menopause
Talkspace and Labcorp’s Ovia Health Form Women’s Health Coalition to Deliver Accessible, Affordable Solutions to Address Women’s Diverse Health Needs
Conceive, Evernow, FitOn, Nurx, Cove, and Nutrium Join as Founding Members to Support the Coalition’s Focus on Expanding Access to...
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ETDevelopment Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive...
ARC Fertility Named Finalist for Two Categories at FemTech World Awards 2024
CUPERTINO, Calif.--(BUSINESS WIRE)--ARC Fertility (ARC), a highly experienced national provider of innovative fertility and family-forming benefits for self-insured employers and...
Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...
The Fibroid Foundation Announces National Menstrual Health Awareness Month
May is National Menstrual Health Awareness Month - May 28 is International Menstrual Hygiene DayROCKVILLE, MD / ACCESSWIRE / May...
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
Daré joins a nationwide network working to accelerate transformative health solutionsSAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience,...
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
$22 million of non-dilutive capital at close provides significant capital to achieve objectives Upon achieving a pre-specified return threshold, XOMA...
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
Conference Call and Webcast Today at 4:30 p.m. ET2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2%...
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it...
Bone Health Technologies Secures $5 Million in Funding to Transform Osteopenia Care
BHT closes oversubscribed financing round, adds new investors to revolutionize low bone density treatmentsREDWOOD CITY, CA / ACCESSWIRE / March...
Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND...
Pvolve Expands Leadership Team Following Year of Exponential Growth
Fast-scaling fitness company hires Stacey Heald as new Chief Operating Officer of Franchise Development and Alexis McDowel as first global...
Daré Bioscience Announces Executive Team and Board of Directors Changes
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today...
Bone Health Technologies Announces FDA Clearance of OsteoboostTM, the First Prescription Medical Device to Treat Low Bone Density
Osteoboost is the first and only non-pharmacological prescription treatment to demonstrate reduced loss of bone strength in postmenopausal womenRepresents the...
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
Grant funds support activities that will aid the ultimate development of bacteria-based biotherapeutic products designed to benefit women and newbornsSAN...
Daré Bioscience’s DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women’s Health as well as in Treating a Broad Range of Diseases
Strategic Process Underway to Explore Partnering Opportunities for Additional Indications such as with GLP-1s for Obesity and Metabolic Disorders and...
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
$5 million at closing and up to $7 million of additional committed fundingSAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) --...
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
Data Support Continued Clinical Development of DARE-PDM1 and its Potential as a First-in-Category Treatment for Primary DysmenorrheaSAN DIEGO, Dec. 20,...
Women’s Health Associates Selects AI-powered, Ambient Listening Technology Sunoh.ai to Transform Clinical Documentation and Improve Quality Care
The women’s health practice aims to streamline documentation, provide personalized attention to its patients, and drive efficiencies by leveraging the...